The International Generic and Biosimilar Medicines Association (IGBA) is a global organization that focuses on promoting patient access to quality, safe, and effective medicines at affordable prices. With a history dating back to 1997, IGBA has been at the forefront of advocating for the use of generic and biosimilar medicines to address the increasing demands on healthcare services worldwide. IGBA consists of Full Members, Associate Members, and Observers, all of whom are national and regional associations dedicated to advancing the interests of generic and biosimilar medicines.

The association actively participates in various committees such as the Science Committee, International Trade & IP Committee, and the Biosimilars Committee to ensure continuous progress and development in the industry. Through its collaborations with international bodies and its status as an Accredited WIPO Observer and a non-State actor in official relations with WHO, IGBA plays a crucial role in increasing global patient access to affordable, high-quality medicines. The association maintains constant dialogue with other organizations to further its mission and vision.

For more information or to get in touch with IGBA, visit their website or contact them directly at their Geneva office